Chronic Viral Infection

Inflammation triggers unsustainable immune response

Scientists at the University of Basel discovered a fundamental new mechanism explaining the inadequate immune defense against chronic viral infection. These results may open up new avenues for vaccine development.

In the course of an infection or upon vaccination, specialized cells of our immune system, so-called B cells, produce antibodies that bind viruses and inactivate them. In the context of chronic viral infections such as HIV or hepatitis C virus, however, antibody production by B cells is quantitatively inadequate and starts too late.

A team of scientists headed by Prof. Daniel Pinschewer at the Department of Biomedicine, University of Basel, reports that the inadequate antibody response to chronic viral diseases is due to the strong inflammatory reaction upon infection. While most pronounced at the onset of an infection, inflammation can persist for decades, especially in HIV/AIDS.

Hasty immune response lasts only short-term

Under the influence of inflammatory messengers, so called interferons, B cells produce as many antibodies as they possibly can. Unfortunately, this hasty response occurs at the expense of sustainability. B cells that turn on antibody production too quickly lose their potential to proliferate and die shortly thereafter. As a consequence, the immune response takes an impetuous start but subsides rapidly.

The scientists assume that this panic reaction of B cells reflects a mechanism ensuring an optimized response to acute life threatening infections. In the context of chronic infections, however, the battle is not decided within a matter of days, but rather only after months or years. Under these circumstances, the hasty reaction of our body seems inappropriate and may actually favor the virus.

Cornerstone for new vaccines

For viral diseases such as HIV or hepatitis C protective vaccines remain unavailable. The scientists are hopeful that the discovery of this fundamental mechanism may provide a basis to improve vaccination strategies against chronic viral diseases.


Original article
Fallet et al.: Interferon-driven deletion of antiviral B cells at the onset of chronic infection; Sci. Immunol. 1, eaah6817 (2016) | doi: 10.1126/sciimmunol.aah6817

Source: University of Basel

24.10.2016

More on the subject:
Read all latest stories

Related articles

Photo

Myths around SARS-CoV-2 busted

Coronavirus FAQ to dispel fake and harmful advice

The current outbreak of the novel coronavirus disease (COVID-19) is making headlines by the minute. However, some less-than-trustworthy advice can be found among the information. Understandably, many…

Photo

COVID-19 infection control

Combatting the novel coronavirus with thorough hand hygiene

WHO Chief Adhanom Ghebreyesus has declared the novel coronavirus (SARS-CoV-2) a global health emergency. He said the decision was reached not because of the situation in China, but because of,…

Photo

Smart infection control

China uses AI to combat the novel coronavirus outbreak

Infrared thermometers are now used in most subway stations in China to prevent the spread of novel coronavirus (SARS-CoV-2) pneumonia (MCP). Many stations have implemented an artificial intelligence…

Related products

Atlas Genetics - Atlas Genetics io system

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd
Siemens Healthineers – Versant HCV Genotype 2.0 Assay (LiPA)

Infectious Disease/Hepatitis

Siemens Healthineers – Versant HCV Genotype 2.0 Assay (LiPA)

Siemens Healthineers